Key Highlights

  • Loss per share was USD 1.02 against an estimate of a USD 0.84 loss.
  • Net loss was USD 1.53 million, compared with USD 1.60 million.
  • Operating expenses were USD 1.72 million, compared with USD 1.37 million.
  • Cash was USD 1.52 million and restricted cash was USD 3.43 million.

ENDRA Life Sciences (NASDAQ:NDRA) reported a third quarter 2026 net loss of USD 1.53 million, compared with USD 1.60 million in the prior-year quarter. Net loss per share was USD 1.02, compared with USD 2.10, against an estimate of a USD 0.84 loss.

The filing reports no Revenue for the quarter. It describes a digital asset treasury strategy under which the company may acquire, hold and deploy digital assets, which consist primarily of HYPE tokens.

Third Quarter Results

Research and development expense was USD 176.28 thousand, compared with USD 432.11 thousand, and general and administrative expense was USD 1.54 million, compared with USD 893.31 thousand. Total operating expenses were USD 1.72 million, compared with USD 1.37 million.

Other income and expense items included an unrealized gain on digital Assets of USD 168.05 thousand, a realized gain of USD 341.87 thousand and digital asset management and performance fees of USD 246.87 thousand. The change in Fair Value of the Warrant Liability was USD 77.17 thousand, compared with USD 267.27 thousand.

Total other income was USD 186.64 thousand, compared with total other expense of USD 225.26 thousand in the prior-year quarter. Weighted average shares outstanding were 1,499,838, compared with 761,218.

Nine-Month Results

For the nine months ended September 30, 2026, total operating expenses were USD 5.37 million, compared with USD 4.14 million, and the unrealized gain on digital assets was USD 2.20 million. The net loss was USD 2.68 million, compared with USD 3.86 million.

Net loss per share for the nine months was USD 2.00, compared with USD 5.68.

Balance Sheet and Going Concern Disclosure

Cash was USD 1.52 million at September 30, 2026, compared with USD 794.04 thousand at December 31, 2025, and restricted cash was USD 3.43 million. Total assets were USD 6.72 million, compared with USD 3.85 million.

Total liabilities were USD 1.52 million, compared with USD 1.59 million, and current liabilities were USD 635.72 thousand, compared with USD 750.96 thousand. The filing discloses substantial doubt about the company's ability to continue as a going concern.

Net cash used in Operating Activities for the nine months was USD 3.80 million, compared with USD 3.57 million. Total current assets were USD 5.05 million, compared with USD 967.97 thousand at December 31, 2025, and total stockholders' Equity was USD 5.20 million, compared with USD 2.26 million.

The accumulated Deficit was USD 113.15 million, compared with USD 110.47 million. The filing states that the company had USD 4.94 million in cash, of which approximately USD 3.4 million is subject to restrictions on use under a deposit account control agreement. Depreciation and amortization for the nine months was USD 25.58 thousand, compared with USD 33.93 thousand.

ENDRA Life Sciences Q3 2026 Earnings: Key Takeaways

ENDRA Life Sciences reported a third quarter 2026 net loss of USD 1.53 million and a loss per share of USD 1.02. Cash was USD 1.52 million at September 30, 2026.